EEG patterns and cognitive outcomes in chronic respiratory disorders: a systematic review.

Clin NeurophysiolJun 23, 2026 (epub)
Clinical ResearchPulmonology

Gianvito Lagravinese, Paola Santacesaria, Giorgio Castellana et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined the relationship between EEG patterns and cognitive impairment in adults with chronic respiratory disorders, focusing primarily on obstructive sleep apnea (OSA). The review included 44 studies and identified three main EEG abnormalities associated with cognitive deficits, particularly in attention and memory. The findings highlight the potential of EEG as a marker for cognitive vulnerability in these patients.

Key findings

  • Prolonged event-related latencies, especially P300 latency, were frequently observed.
  • Alterations in sleep EEG microstructure, including spindle and slow-oscillation abnormalities, were noted.
  • EEG abnormalities correlated with impairments in attention, executive functioning, and memory consolidation.

Why it matters

Understanding the EEG correlates of cognitive impairment in chronic respiratory disorders can help clinicians identify patients at risk for cognitive decline, potentially guiding monitoring and intervention strategies.

Source

PubMed · PMID 42349048

Published in Clin Neurophysiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.